Pharma & Bio
Technology
Lundbeck Explores Other Indications for 'APB-A1'… "A Negative Sign, Even If Development Isn't Halted"
AprilBio Co.,Ltd.(397030)has decided to explore other indications for “APB-A1” (Lu AG22515), a technology it licensed to Lundbeck, after the compound failed to demonstrate the expected clinical effica…
Technology
U.S. FDA Approves Anticancer Virus for the First Time in 11 Years… Positive News for SillaJen, Inc.’s ‘SJ-600’
With the U.S. Food and Drug Administration (FDA) approving a new oncolytic virus therapy for the first time in about 11 years, attention in South Korea is turning to SillaJen, Inc.(215600), which is d…
Lifestyle
Remedi Surges 23%; Bio Solution Climbs on China Expansion [K-bio pulse]
Portable X-ray manufacturer Remedi saw its stock price surge after reporting explosive earnings growth. The company is expanding rapidly not only in South Korea but also overseas, raising expectations…
Lifestyle
Remedy Soars 23% on Strong Earnings… Bio Solution Co.,Ltd., Expanding into China, Also Draws Attention [Bio Spotlight]
The stock price of #Remedy, a portable X-ray company, rose sharply as the company posted explosive earnings growth. As Remedy continues to grow rapidly both domestically and internationally, it is exp…
Technology
Inbosa Faces Setbacks, Cartistem Succeeds… “Pain,” the Biggest Challenge, Determined Success or Failure
As TG-C (formerly Invossa) from Kolon TissueGene, Inc.(950160)failed to demonstrate pain relief in its U.S. Phase 3 clinical trial, “pain”—considered the biggest challenge in the development of osteoa…
Lifestyle
SEERS Sold for 1,000 Won, Net Profit of 440 Won... Pharmaceuticals, Biotech, and Healthcare Rank 'Top in Profitability'
#SEERS Technology is rapidly emerging as the most profitable company among domestic pharmaceutical, biotech, and healthcare firms. In the first half of this year, the company generated 26.8 billion wo…
Technology
Curiox Hits Limit-Up; CPS Overhang Weighs on OliX [K-Bio Pulse]
On Aug. 14, Curiox Biosystems hit the daily upper limit after announcing a “multi-unit” order from a global pharmaceutical company. OliX Pharmaceuticals, meanwhile, extended its losing streak to four …
Technology
Curiox Rises on 'Multi-Unit' Order… Olix Pharmaceuticals, Inc. Hindered by CPS Overhang [Bio Spotlight]
On the 14th, in the biotech and healthcare sector, Curiox hit the daily price limit following news that it had secured a “multi-unit” order from a global pharmaceutical company. Meanwhile, Olix Pharma…
Lifestyle
Park Dong-hyun, CEO of Mezion Pharma Co., Ltd.: “A 20-Year Battle for Udenafil… Moving Beyond Fontan to ADPKD”
“While developing Udenafil over the past 20 years, we reviewed countless other new drug candidates. But in the end, we couldn’t find a compound as promising as this one.”Park Dong-hyun, CEO (Chairman)…
Technology
A Closer Look at Kori Group’s Financial Statements Amid the ‘Accounts Receivable Controversy’… Operating Cash Flow Deficit Persists
Screenshot of the Cory Group website.
As concerns arise over the possibility that Beijing Hanmi, a Chinese subsidiary of Hanmi Group, may be unable to collect its accounts receivable, attention is…